2018 Q4 Form 10-K Financial Statement

#000167479620000011 Filed on April 09, 2020

View on sec.gov

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Entity File Number EntityFileNumber	000-15303
CY2019	dei	Entity Registrant Name EntityRegistrantName	HST GLOBAL, INC.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	73-1215433
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	150 Research Drive
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Hampton
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	23666
CY2019	dei	City Area Code CityAreaCode	757
CY2019	dei	Local Phone Number LocalPhoneNumber	766-6100
CY2019Q4	dei	Entity Public Float EntityPublicFloat	96779	usd
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4247993	shares
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1955	usd
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1955	usd
CY2018Q4	us-gaap	Assets Current AssetsCurrent	0	usd
CY2019Q4	us-gaap	Assets Assets	1955	usd
CY2018Q4	us-gaap	Assets Assets	0	usd
CY2019Q4	us-gaap	Bank Overdrafts BankOverdrafts	0	usd
CY2018Q4	us-gaap	Bank Overdrafts BankOverdrafts	2957	usd
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3910	usd
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3228	usd
CY2019Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1475	usd
CY2018Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	505959	usd
CY2019Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	0	usd
CY2018Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	1110000	usd
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	376629	usd
CY2019Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	usd
CY2018Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1372169	usd
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5385	usd
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3370942	usd
CY2019Q4	us-gaap	Liabilities Liabilities	5385	usd
CY2018Q4	us-gaap	Liabilities Liabilities	3370942	usd
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4247993	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4247993	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2447991	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2447991	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	4248	usd
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	2448	usd
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5358236	usd
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2419096	usd
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5365914	usd
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5792486	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-3430	usd
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-3370942	usd
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1955	usd
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	0	usd
CY2019	us-gaap	Revenues Revenues	0	usd
CY2018	us-gaap	Revenues Revenues	0	usd
CY2019	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	80206	usd
CY2018	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	120000	usd
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	71348	usd
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22587	usd
CY2019	us-gaap	Operating Expenses OperatingExpenses	151554	usd
CY2018	us-gaap	Operating Expenses OperatingExpenses	142587	usd
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-151554	usd
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-142587	usd
CY2019	us-gaap	Interest Expense InterestExpense	17874	usd
CY2018	us-gaap	Interest Expense InterestExpense	35748	usd
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	596000	usd
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	578126	usd
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-35748	usd
CY2019	us-gaap	Net Income Loss NetIncomeLoss	426572	usd
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-178335	usd
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.13
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3268814	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2447990	shares
CY2019	us-gaap	Profit Loss ProfitLoss	426572	usd
CY2018	us-gaap	Profit Loss ProfitLoss	-178335	usd
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	596000	usd
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2019	us-gaap	Increase Decrease In Book Overdrafts IncreaseDecreaseInBookOverdrafts	2957	usd
CY2018	us-gaap	Increase Decrease In Book Overdrafts IncreaseDecreaseInBookOverdrafts	-2957	usd
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2606	usd
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1461	usd
CY2019	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	60000	usd
CY2018	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	120000	usd
CY2019	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	17874	usd
CY2018	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	35748	usd
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-91905	usd
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21091	usd
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80000	usd
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2019	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	13860	usd
CY2018	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	20800	usd
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	93860	usd
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20800	usd
CY2019	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1955	usd
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-291	usd
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291	usd
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1955	usd
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2019	us-gaap	Interest Paid InterestPaid	0	usd
CY2018	us-gaap	Interest Paid InterestPaid	0	usd
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2019	fil	Conversionof Accounts Payable ConversionofAccountsPayable	1509680	usd
CY2018	fil	Conversionof Accounts Payable ConversionofAccountsPayable	0	usd
CY2019	fil	Conversionof Notes Payable ConversionofNotesPayable	985296	usd
CY2018	fil	Conversionof Notes Payable ConversionofNotesPayable	0	usd
CY2019	fil	Derecognition Of Related Party Debt DerecognitionOfRelatedPartyDebt	365964	usd
CY2018	fil	Derecognition Of Related Party Debt DerecognitionOfRelatedPartyDebt	0	usd
CY2019	us-gaap	Nature Of Operations NatureOfOperations	<b>NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES</b> HST Global, Inc. (“the Company”) was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation. The Company has made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a Merger and share exchange agreement with Health Source Technologies, Inc. This business acquisition has been accounted for as a reverse merger or recapitalization of Health Source Technologies, Inc. At the time of the merger NT Holding Corporation had disposed of its assets and liabilities and had minimal operations. Immediately after the acquisition the Company changed its name to HST Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of the State of Nevada on August 6, 2007. The Company is currently headquartered in Hampton, Virginia. HST Global, Inc. is an integrated Health and Wellness Biotechnology company with a plan to develop and/or acquire a network of Wellness Centers worldwide with the primary focus on homeopathic and alternative treatments of late stage cancer and other life threatening diseases.  In addition, the Company intends to acquire innovative products for the treatment of life threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer and/or life threatening diseases. To date we have been unable to initiate our original business plan.  While we are continuing to seek opportunities to do so, we are also seeking other opportunities to integrate assets, rights, or other potential revenue streams.
CY2019	us-gaap	Basis Of Accounting BasisOfAccounting	<span style="border-bottom:1px solid #000000">Basis of Presentation</span> The accompanying consolidated financial statements and related notes include the activity of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-K.
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<span style="border-bottom:1px solid #000000">Use of Estimates</span> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2019Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	usd
	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	effect a reverse stock split of all the outstanding shares of the Corporation’s common stock at an exchange ratio of 1 post-split share for 15 pre-split shares (1:15);
CY2019Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	800000	shares
CY2019Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	80000	usd
CY2019	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	89580	usd
CY2018	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-37450	usd
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-89580	usd
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	37450	usd
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1148233	usd
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1237814	usd
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	113692	usd
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	113692	usd
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1034542	usd
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1124122	usd
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd

Files In Submission

Name	View Source	Status
hstc-20191231_lab.xml	Edgar Link	unprocessable
0001674796-20-000011-index-headers.html	Edgar Link	pending
0001674796-20-000011-index.html	Edgar Link	pending
0001674796-20-000011.txt	Edgar Link	pending
0001674796-20-000011-xbrl.zip	Edgar Link	pending
exhibit31-1.htm	Edgar Link	pending
exhibit31-2.htm	Edgar Link	pending
exhibit32-1.htm	Edgar Link	pending
exhibit32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hstc-20191231.htm	Edgar Link	pending
hstc-20191231.xsd	Edgar Link	pending
hstc201912311.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
hstc-20191231_cal.xml	Edgar Link	unprocessable
hstc-20191231_def.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hstc-20191231_pre.xml	Edgar Link	unprocessable
hstc-20191231_htm.xml	Edgar Link	completed